CDK4 and synovial sarcoma: However, as a critical part of the Cyclin D/CDK4/6/Rb axis, the expression and clinical significance of CDK4, and the potential mechanism of targeting CDK4 using the specific inhibitor palbociclib as a putative therapeutic strategy, remains to be elucidated in synovial sarcoma.